NERVIANO, IT and BOSTON, Mass, November 2, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Tiziano Lazzaretti as its new Chief Financial Officer (CFO). Tiziano brings a wealth of leadership experience in corporate strategies, finance, and governance, acquired across diverse industries, including chemicals, pharmaceuticals and biotechnology sectors.
With a proven track record of scaling business operations, managing cross-functional projects, and securing transformative deals, Tiziano is well-prepared to support NMS Group into its next phase of growth. His expertise in strategic and business turnarounds, M&A transactions, and preparing companies for listing on stock exchanges, including Nasdaq and the London Stock Exchange, positions him as a key strategic partner to the executive leadership team.
Before joining NMS Group, Tiziano held executive positions at Accenture, Snia Spa, Walgreen Boots, Teva, and various British-American biotech public listed start-ups, culminating in his last role as CFO of a Swiss-based biotech platform company.
We are delighted to welcome Tiziano to our team,” said Hugues Dolgos, Pharm.D., Chief Executive Officer. “Tiziano’s extensive financial acumen and deep understanding of the biotech sector make him the ideal candidate to help us achieve our strategic objectives and drive our mission to improve patient health through groundbreaking innovations.”
“I am extremely honored and privileged to be appointed Chief Financial Officer and grateful for the trust and support from the management team and the Board,” said Tiziano. “I am thrilled to join the company at a significant inflection point and highly committed to driving a game-changing development process, with the support of a high-standing professional team.”
As CFO, Tiziano will oversee all financial functions, including budgeting, financial reporting, investment strategy, and capital allocation. His leadership will be instrumental in supporting NMS’s ongoing research and development efforts to advance our pipeline, as well as our commitment to delivering cutting-edge solutions that have a positive impact on patient lives. NMS Srl looks forward to leveraging Tiziano’s expertise and leadership to achieve new milestones and drive financial excellence.